A Multicenter Phase II/II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of VPM1002 in the Prevention of Tuberculosis (TB) Recurrence in Pulmonary TB Patients After Successful TB Treatment in India

Post Date: 
2018-01-23
   |   
Countries: 
   |   
Clinical Sites: 
Summary: 

Dr. Vidya Mave is leading this clinical trial evaluating the safety and efficacy of a new recombinant BCG vaccine, VPM1002, in preventing TB recurrence among former pulmonary TB patients who have successfully completed first line anti-TB treatment (ATT) and were declared cured. The RePORT India Consortium is participating in this effort.

Collaborators: